Eventide Asset Management, LLC 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 12:18 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Eventide Asset Management, LLC | 3,332,005 5.030% |
-298,008 (-8.21%) |
Filing |
| 2024-02-14 11:48 am Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Eventide Asset Management, LLC | 3,630,013 6.640% |
3,630,013 (New Position) |
Filing |